Phenelzine and Cardiac Risk
Phenelzine is contraindicated in patients with congestive heart failure and should be avoided in those with cardiovascular disease due to significant risks of hypertensive crises, orthostatic hypotension, and potential myocardial injury. 1
Primary Cardiac Contraindications
The FDA label explicitly contraindicates phenelzine in patients with:
These are absolute contraindications based on the drug's mechanism and documented adverse effects.
Major Cardiovascular Risks
Hypertensive Crises
Phenelzine's most dangerous cardiac risk is hypertensive crisis, which occurs through two mechanisms:
Tyramine-induced: Ingestion of tyramine-rich foods (aged cheeses, pickled herring, beer, wine, fermented products) can trigger severe hypertension 1. A documented case report demonstrated myocardial infarction following cheese ingestion in a patient on phenelzine, with troponin I peaking at 4.89 µg/L 2.
Drug-induced: Concomitant use with sympathomimetic drugs (amphetamines, cocaine, methylphenidate, dopamine, epinephrine, norepinephrine) or related compounds (methyldopa, L-dopa) is absolutely contraindicated 1.
Orthostatic Hypotension
Phenelzine causes marked impairment of blood pressure regulation upon standing:
- 83% of phenelzine-treated patients lack the normal initial blood pressure overshoot when standing (compared to 15% with moclobemide) 3
- Median time for diastolic BP recovery is 14.5 seconds (vs 4.9 seconds with moclobemide) 3
- Standing diastolic BP change is only 4 mmHg (vs 15 mmHg with moclobemide) 3
- This occurs in hypertensive, normotensive, and hypotensive patients alike 1
The mechanism involves impaired sympathetic function while parasympathetic responses remain preserved 3.
Other Cardiovascular Effects
- QTc interval shortening (unlike tricyclics which prolong QTc) 4
- Heart rate slowing (opposite to tricyclic effects) 4
- Significant blood pressure decreases correlated with degree of MAO inhibition 4
Clinical Management Algorithm
Pre-Treatment Assessment
Do NOT initiate phenelzine if:
Obtain baseline:
- Blood pressure (supine and standing)
- ECG (assess for conduction abnormalities, baseline QTc)
- Complete medication list to identify contraindicated drugs
During Treatment Monitoring
Blood pressure monitoring:
- Check supine and standing BP at each visit
- Monitor for orthostatic symptoms (dizziness, syncope)
- Note: Reported dizziness does NOT correlate with measured BP changes 4, so objective measurement is essential
Dietary compliance:
- Strict avoidance of high-tyramine foods
- Avoid excessive caffeine and chocolate
- Provide written list of prohibited foods 1
Drug interactions:
- Maintain 14-day washout period before/after other MAOIs 1
- Never combine with sympathomimetics 1
- Contraindicated with meperidine (risk of excitation, seizures, delirium, circulatory collapse) 1
- Contraindicated with serotoninergic agents (SSRIs, SNRIs, venlafaxine) - requires 14-day washout, except fluoxetine which requires longer 1
Emergency Management
If hypertensive crisis occurs:
- Alpha blockade and fluid loading with invasive hemodynamic monitoring 5
- Elevated plasma and urinary catecholamines confirm diagnosis 5
- Contracted blood volume requires aggressive fluid resuscitation 5
Critical Pitfalls to Avoid
Biphasic blood pressure response: Patients may develop hypertensive crisis followed by hypotension requiring fluid resuscitation 2. One case demonstrated hypotension 4 hours after a therapeutic phenelzine dose following initial hypertensive crisis, requiring >2L IV fluid boluses 2.
Delayed myocardial injury: Troponin elevation may not peak until 6 hours after symptom onset 2.
Sympathetic impairment is profound: The 83% rate of absent BP overshoot on standing represents severe autonomic dysfunction 3.
Diabetes interaction: Phenelzine increases insulin sensitivity; hypoglycemic agent requirements may decrease 1.
Use in Specific Cardiac Populations
Ischemic heart disease: While not explicitly contraindicated, the risk of hypertensive crisis leading to myocardial infarction 2 and the profound orthostatic effects 3 make phenelzine unsuitable for patients with coronary artery disease.
Post-MI patients: Phenelzine should be avoided. Standard post-MI therapy includes beta-blockers and ACE inhibitors 6, which may interact unpredictably with phenelzine's autonomic effects.
Heart failure: Absolute contraindication 1.
Bottom line: Phenelzine should rarely be used in any patient with cardiovascular disease or risk factors, and only when other antidepressants have failed and the psychiatric indication is severe enough to justify the substantial cardiac risks 1.